Beta Bionics director gets 3,997-share stock award

Beta Bionics, Inc. director Maria Palasis reported receiving a grant of 3,997 shares of common stock on January 13, 2026.

Rhea-AI Filing Summary

Beta Bionics, Inc. director Maria Palasis reported receiving a grant of 3,997 shares of common stock on January 13, 2026. The transaction is coded as an acquisition at a price of $0 per share and is described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this award, Palasis beneficially owns 12,432 shares of Beta Bionics common stock, held in direct ownership.

Insider Trade Summary

Grant/Award: 3,997 shares

Grant/Award 1 txn

Insider Palasis Maria

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,997	$0.00	$0.00

Holdings After Transaction: Common Stock — 12,432 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BBNX report for Maria Palasis?

The filing reports that director Maria Palasis acquired 3,997 shares of Beta Bionics common stock on January 13, 2026.

What type of shares did Maria Palasis receive in this BBNX Form 4?

The filing states the shares represent a restricted stock unit award granted under Beta Bionics 2025 Equity Incentive Plan.

At what price were the 3,997 Beta Bionics (BBNX) shares granted to the director?

The 3,997 shares of Beta Bionics common stock were reported with a transaction price of $0 per share, consistent with a restricted stock unit award.

How many Beta Bionics (BBNX) shares does Maria Palasis own after this transaction?

After the award, Maria Palasis beneficially owns 12,432 shares of Beta Bionics common stock.

Is the ownership reported by Maria Palasis in BBNX direct or indirect?

The Form 4 shows the 12,432 shares are held with direct (D) ownership by Maria Palasis.

What is Maria Palasis relationship to Beta Bionics (BBNX)?

The filing identifies Maria Palasis as a director of Beta Bionics, Inc., with no officer or 10% owner status indicated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 08:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palasis Maria

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		A		3,997(1)	A	$0	12,432	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.